Immix Biopharma (Nasdaq: IMMX)

Our N-GENIUS cell therapy platform has three key elements: 1) A purpose-built cell therapy evidence capture engine paired with a relational database 2) Our proprietary EXPAND technology, instrumental in developing our groundbreaking NXC-201 3) An atomized binding scaffold generation engine, facilitating precise binding for every molecule With these advancements, the future looks promising in the battle against AL Amyloidosis! #ALAmyloidosis #celltherapy

Approximately 70,000 individuals are currently battling AL Amyloidosis, and moving forward demands taking small steps toward progress. Whether it's our upcoming clinical trials or raising awareness, we're enthusiastic about contributing to the ultimate goal of 0 active AL Amyloidosis cases. #biopharma #clinicaltrials #ALAmyloidosis

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma Read the Press Release: https://loom.ly/W63cAjY #multiplemyeloma #biopharma

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial Read the Article: https://lnkd.in/g4dY4VTH #biopharma #cancertreatment #clinicaltrail

In the words of our CEO @Ilya Rachman: “Through our many conversations with AL Amyloidosis patients, it has become apparent that an awareness campaign to effect shorter timelines-to-diagnosis for patients who could benefit from earlier treatments is necessary. We are proud to make the voices of these patients heard, to motivate greater awareness in the medical community.” Let's keep bringing awareness to this important disease together! https://lnkd.in/dVygtDyH

Optimism is the fuel of any life science company. But, along with optimism…we need to have a lot of "realism" sprinkled in. We're looking for like-minded leaders (and investors) to join our journey! #biopharma #science #investor

The human body is too unique to rely on generic, one-size-fits-all cancer treatment. This belief is behind much of our CAR-T therapy innovation here at Immix Biopharma. #cart-t #cancertreatment #cancertherapy

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative Read the article here: https://lnkd.in/eWMj9XbR #alamyloidosis #pharma

One of the biggest advantages of our N-GENIUS technology is the ability to gather preliminary clinical data QUICKLY. Speed is critical in immunology and the faster we can generate a feedback loop, the better our chances of helping patients. #immunology #biopharma #celltherapy

𝗤𝗨𝗘𝗦𝗧𝗜𝗢𝗡: What is CAR-T cell therapy? 𝗔𝗡𝗦𝗪𝗘𝗥: A type of cancer treatment where a patient's T cells are modified in a lab to attack diseased cells. All with the goal of killing bad cells without hurting the good ones! In case you didn't know, this is what we're great at here at Immix Bio. #celltherapy #cancertherapy #biopharma